AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

India Globalization Capit... (IGC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.30

0.01 (2.11%)

At close: Feb 20, 2025, 3:59 PM

0.30

1.35%

After-hours: Feb 20, 2025, 06:34 PM EST

undefined% (undefined)

Bid	0.3
Market Cap	23.61M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.12
PE Ratio (ttm)	-2.47
Forward PE	n/a
Analyst	Strong Buy

Ask	0.3
Volume	182,823
Avg. Volume (20D)	425,062
Open	0.30
Previous Close	0.29
Day's Range	0.29 - 0.30
52-Week Range	0.27 - 0.91
Beta	undefined

About IGC

India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. It operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. It also develops cannabinoid-based products and therapies, such as hemp-based tinctures to treat anxiety, and enhance the lifestyle of patients suffering from...

[Show more]

Industry Conglomerates

Sector Industrials

IPO Date May 24, 2006

Employees 67

Stock Exchange AMEX

Ticker Symbol IGC

Website https://www.igcinc.us

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for IGC stock is "Strong Buy." The 12-month stock price forecast is $3.75, which is an increase of 1165.61% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

India Globalization Capital Inc. is scheduled to release its earnings on Mar 4, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

+20.56%

Shares of cannabis stocks are trading higher follo... Unlock content with Pro Subscription

4 months ago

+1.17%

IGC Pharma shares are trading higher after a Form 4 filing showed that company director James P. Moran purchased 588,235 shares of common stock at $0.34 per share.

News

16 hours ago · accessnewswire.com

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

- New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function - POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:I...

2 days ago · accessnewswire.com

IGC Pharma Reports Third Quarter Fiscal 2025 Results

POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended...

6 days ago · zacks.com

IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates

IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.

1 week ago · accessnewswire.com

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

- Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy - POTOMAC, MD / ACCESS Newswire / February 11, 2025 / IGC Pharma, Inc...

3 weeks ago · zacks.com

IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock?

IGC Pharma, Inc. (IGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

3 weeks ago · accessnewswire.com

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE...

2 months ago · zacks.com

What Makes IGC Pharma, Inc. (IGC) a New Buy Stock

IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · businesswire.com

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment.